Home » Stocks » ORTX

Orchard Therapeutics PLC (ORTX)

Stock Price: $6.25 USD -0.25 (-3.85%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
After-hours: $6.30 +0.05 (0.80%) Jan 21, 7:58 PM
Market Cap 610.93M
Revenue (ttm) 3.19M
Net Income (ttm) n/a
Shares Out 99.66M
EPS (ttm) -1.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $6.25
Previous Close $6.50
Change ($) -0.25
Change (%) -3.85%
Day's Open 6.60
Day's Range 6.17 - 6.62
Day's Volume 1,537,045
52-Week Range 3.86 - 13.48

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

BOSTON and LONDON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced plans to extend the company's commercial reach in the Mi...

Zacks Investment Research - 6 days ago

The FDA bestows a Regenerative Medicine Advanced Therapy status on Orchard Therapeutics' (ORTX) investigational gene therapy, OTL-200, for treating early-onset metachromatic leukodystrophy. Sh...

InvestorPlace - 2 weeks ago

Orchard Therapeutics (ORTX) stock is on the rise Wednesday with heavy trading even with there being no major news about the company. The post ORTX Stock Alert: 8 Things to Know About Gene Ther...

GlobeNewsWire - 2 weeks ago

BOSTON and LONDON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the 39th Ann...

GlobeNewsWire - 1 month ago

First gene therapy to receive full EU marketing authorization for eligible MLD patients

Zacks Investment Research - 1 month ago

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: AUDC, BLCM, INUV
GlobeNewsWire - 1 month ago

Preliminary results from first patient treated with OTL-201 show over expression of the therapeutic enzyme and decrease in substrate levels three months following gene therapy Preliminary resu...

GlobeNewsWire - 1 month ago

BOSTON and LONDON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that its chief executive officer, Bobby Gaspar, M.D., Ph...

GlobeNewsWire - 2 months ago

BOSTON and LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the U.S. Food and Drug Administration (FDA) has cle...

The Motley Fool - 2 months ago

These companies are devoted to helping patients who don't have any other options.

Other stocks mentioned: ALXN
GlobeNewsWire - 2 months ago

BOSTON and LONDON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the Barclays...

GlobeNewsWire - 2 months ago

Preliminary results from first patient in ongoing proof-of-concept trial show evidence of engraftment of gene-modified cells three months following treatment Preliminary results from first pat...

Seeking Alpha - 2 months ago

Orchard just received a positive node from CHMP for its lead drug candidate. US approval should be next.

GlobeNewsWire - 2 months ago

BOSTON and LONDON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will webcast a virtual R&D event ‘New H...

GlobeNewsWire - 2 months ago

BOSTON and LONDON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company's chief executive officer, Bobby Gaspar...

GlobeNewsWire - 3 months ago

First therapy recommended for full marketing authorization in the EU for eligible patients with confirmed diagnosis of late infantile or early juvenile MLD variants

GlobeNewsWire - 3 months ago

BOSTON and LONDON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the European Medicines Agency (EMA) has granted ...

GlobeNewsWire - 4 months ago

BOSTON and LONDON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the follo...

GlobeNewsWire - 4 months ago

Data on all eight patients demonstrate sustained engraftment and supranormal IDUA enzyme expression

The Motley Fool - 4 months ago

No news is good news for this biotech company.

GlobeNewsWire - 4 months ago

BOSTON and LONDON, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced presentations at the upcoming 46th Annual Meeting of t...

Seeking Alpha - 5 months ago

Orchard Therapeutics plc (ORTX) CEO Bobby Gaspar on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

BOSTON and LONDON, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the Wedbus...

Seeking Alpha - 5 months ago

Orchard Therapeutics: An Undervalued Gene Therapy Company

GlobeNewsWire - 6 months ago

BOSTON and LONDON, July 20, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company has received both orphan drug designa...

GlobeNewsWire - 6 months ago

BOSTON and LONDON, July 15, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company has entered into two worldwide royalt...

GlobeNewsWire - 6 months ago

BOSTON and LONDON and MILAN, Italy, July 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, and MolMed S.p.A (MLMD.MI), one of the company’s prin...

GlobeNewsWire - 7 months ago

BOSTON and LONDON, May 27, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that presentations by the management team will be made ...

GlobeNewsWire - 8 months ago

First Primary Outcome Measure Met with All Eight Patients Achieving Hematologic Engraftment

Seeking Alpha - 8 months ago

Orchard Therapeutics: A Leading Gene Therapy Company For Your Watchlist

Seeking Alpha - 8 months ago

Orchard Therapeutics' (ORTX) CEO Bobby Gaspar on Q1 2020 Results - Earnings Call Transcript

Benzinga - 8 months ago

Shares of Orchard Therapeutics (NASDAQ:ORTX) fell 1.5% after the company reported Q1 results.

Seeking Alpha - 8 months ago

Orchard Therapeutics: Updating The Investment Thesis

GlobeNewsWire - 8 months ago

BOSTON and LONDON, April 27, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics  (Nasdaq: ORTX), a global gene therapy leader, today announced that the first patient has been dosed in an open-la...

24/7 Wall Street - 9 months ago

The COVID-19 pandemic has changed normal operations for companies across the world as they cope with resource limitations, health precautions and other challenges.

Other stocks mentioned: AVRO, FATE, KNSA, MRSN, NVCR, SYBX, TCRR
GlobeNewsWire - 9 months ago

BOSTON and LONDON, March 31, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global leader in gene therapy, today provided an update on its business and operations, outlining...

GlobeNewsWire - 10 months ago

-- Mark Rothera steps down as President and CEO -- -- Frank Thomas takes on additional responsibilities as President and Chief Operating Officer --

Seeking Alpha - 10 months ago

Orchard Therapeutics PLC (ORTX) CEO Mark Rothera on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 11 months ago

BOSTON and LONDON, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the appointment of Steven Altschuler, M.D., to its boa...

GlobeNewsWire - 11 months ago

Early Clinical Data Support ex vivo Hematopoietic Stem Cell Gene Therapy as a Potentially Promising Treatment Option for X-CGD Early Clinical Data Support ex vivo Hematopoietic Stem Cell Gene ...

GlobeNewsWire - 1 year ago

Application Being Evaluated Under Accelerated Assessment Application Being Evaluated Under Accelerated Assessment

GlobeNewsWire - 1 year ago

BOSTON and LONDON, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients...

Seeking Alpha - 1 year ago

Orchard Therapeutics' (ORTX) CEO on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Registrational Trial for Wiskott-Aldrich Syndrome Met Key Primary and Secondary Endpoints at Three Years; Data from Integrated Analysis Reinforce Treatment Benefits of Gene Therapy and Durabil...

GlobeNewsWire - 1 year ago

Stable Levels of Engraftment and Reconstitution of Enzyme Activity in Patients with Up to 12 Months of Follow-up Indicate Similar Profiles Between Cryopreserved and Fresh Formulations

GlobeNewsWire - 1 year ago

BOSTON and LONDON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients...

GlobeNewsWire - 1 year ago

Initial Results from Cryopreserved Formulation Clinical Trial Accepted as Poster Presentation Initial Results from Cryopreserved Formulation Clinical Trial Accepted as Poster Presentation

GlobeNewsWire - 1 year ago

BOSTON and LONDON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patient...

GlobeNewsWire - 1 year ago

BOSTON and LONDON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patient...

GlobeNewsWire - 1 year ago

Six of Eight Patients Treated to Date with Follow-up Out to 12 Months in First Patient to Receive Treatment

About ORTX

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical develop... [Read more...]

Industry
Biotechnology
IPO Date
Oct 31, 2018
CEO
Prof. Bobby Gaspar Ph.D., M.D.
Employees
252
Stock Exchange
NASDAQ
Ticker Symbol
ORTX
Full Company Profile

Financial Performance

In 2019, ORTX's revenue was $2.51 million, an increase of 21.05% compared to the previous year's $2.08 million. Losses were -$163.42 million, -29.10% less than in 2018.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for ORTX stock is "Strong Buy." The 12-month stock price forecast is 14.56, which is an increase of 132.96% from the latest price.

Price Target
$14.56
(132.96% upside)
Analyst Consensus: Strong Buy